PAM
FPRX

Princeton Alpha Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Princeton Alpha Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,677
Closed -$234K – 806
2016
Q4 		$234K Buy
+4,677
New +$246K 0.05% 556

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Princeton Alpha Management's FPRX Position: Q1 2017 in Review

Princeton Alpha Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2017, closing a stake of 4,677 shares — an estimated $234K sold.

Princeton Alpha Management first reported a position in FPRX in Q4 2016 and held it in 1 quarter. The position peaked at $234K in Q4 2016. 157 funds tracked by Wall St. Rank hold FPRX as of Q1 2017.

  • Princeton Alpha Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
  • Princeton Alpha Management sold 4,677 Five Prime Therapeutics, Inc. shares in Q1 2017, an estimated $234K.
  • Princeton Alpha Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2016 and held it in 1 quarter.
  • Princeton Alpha Management's Five Prime Therapeutics, Inc. position peaked at $234K in Q4 2016.
  • 157 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2017.

Based on Princeton Alpha Management's 13F filing for Q1 2017, filed 3 May 2017.